RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibody yields.
RevoAb®: The Next-Gen AI Antibody Design
Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design.
Key Advantages of RevoAb®
- Speed: Multiple optimized sequence candidates for improved physicochemical properties in a day, not weeks
- Satisfaction: Proven records, 92% success rate, by Japanese pharmaceutical and academic customers (including internal data), particularly with significant improvements in protein expression levels during the pre-launch period beginning July 2025
- Low cost: Starting at $700 USD per antibody for exploring physicochemical property improvements, “Start with RevoAb®, Scale with aiProtein® , high-value, fully customized AI antibody engineering”
- ZERO Complex AI Configurations: No specialized AI and bioinformatics expertise and expert-level AI parameter tuning, making advanced AI design accessible to every researcher
- High Modality and Species Compatibility: Wide-Range of antibody modalities, from monoclonal IgG to the next-gen antibodies, such as variable fragment formats (Fv, VHH) across diverse species including human, mouse, rat, rabbit, chicken, llama, etc.
For details, visit the RevoAb® Service Site: https://revoab.revolka.com/en/
Proven Success in Japan
Throughout the pilot phase, RevoAb® has successfully contributed to solving critical challenges for Japanese pharmaceutical companies, biotech ventures, and universities. The service has earned a strong reputation for its ability, for example, to overcome production issues. An example is shown below. One of the three RevoAb generated sequences of a difficult-to-express single chain Fv showed 7x higher expression levels in E.coli without serious change in affinity.
Background: Minimizing Lead Time and R&D Costs
Antibodies are essential across various industries, from therapeutics to diagnostics. However, optimizing their characteristics, such as stability, affinity, and productivity, remains a significant technical hurdle requiring substantial time and investment.
RevolKa helps to break these barriers by providing researchers worldwide with direct, simple access to the power of aiProtein®. By streamlining the design process, RevoAb® empowers scientists to focus on breakthrough discoveries.
About RevolKa Ltd.
RevolKa is a biotechnology company specialized in protein engineering using its proprietary AI platform, aiProtein®. The company is committed to accelerating the development of novel biologics and industrial enzymes to improve human health and sustainability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260324326476/en/
© Business Wire, Inc.
Advertencia :
Este comunicado de prensa no es un documento producido por AFP. AFP no será responsable de su contenido. Para cualquier pregunta relacionada, por favor póngase en contacto con las personas/entidades mencionadas en el comunicado de prensa.